miR-106b suppresses pathological retinal angiogenesis

Area of Science:

• Molecular Biology
• Ophthalmology
• Genetics

Background:

• MicroRNAs (miRNAs) are key regulators of gene expression.
• Decreased miR-106b levels are observed in neovascular age-related macular degeneration (AMD).
• The unfolded protein response (UPR) pathway, specifically protein kinase RNA-like ER kinase (PERK), influences miRNA expression.

Purpose of the Study:

• To investigate the role of the miR-106b-25 cluster in neovascular AMD.
• To determine the regulatory mechanisms controlling miR-106b expression in AMD.
• To evaluate the therapeutic potential of miR-106b for treating pathological retinal angiogenesis.

Main Methods:

• Utilized a mouse model of neovascular AMD.
• Investigated the regulation of the miR-106b-25 cluster by the PERK-UPR pathway.
• Assessed the impact of miR-106b reduction on angiogenesis in vitro and in vivo.
• Employed lentiviral vectors for therapeutic delivery of miR-106b to the retina.

Main Results:

• Expression of the miR-106b-25 cluster is negatively regulated by the PERK-UPR pathway in a mouse model of neovascular AMD.
• Reduced miR-106b levels promote both in vivo and in vitro vascular growth by upregulating pro-angiogenic factors.
• Therapeutic delivery of miR-106b via lentiviral vectors demonstrated protective effects against aberrant retinal angiogenesis in two distinct mouse models.

Conclusions:

• miR-106b plays a critical role in regulating pathological retinal angiogenesis.
• The PERK-UPR pathway modulates miR-106b expression, impacting AMD pathogenesis.
• miR-106b represents a promising multitarget therapeutic candidate for neovascular AMD and other angiogenesis-driven diseases.